Ultragenyx™ Current Pipeline

Ultragenyx’ lead program, UX001, is being evaluated as a treatment for GNE Myopathy (also known as Hereditary Inclusion Body Myopathy (HIBM)). Other pipeline products are expected to reach the clinical stage within 1-2 years. Additional opportunities that are clinically staged or that may be rapidly translated to the clinic will also be sought.